What is the optimum perioperative drug therapy following lower-extremity vein bypass surgery?
While endoluminal procedures are now commonly done for symptomatic peripheral arterial disease, vein bypass remains the gold standard for revascularization. Lower extremity vein bypass procedure success is dependent on patient factors, surgical judgment and technique, including use of medications. Cardioprotective medications have proven efficacy to decrease morbidity and mortality, but their use to improve graft patency is less well known. We review the up to date use of medications with known vascular effects that may promote graft success, as well as decrease cardiovascular events in this high risk patient group.
Henke
Peter
P
Section of Vascular Surgery, University of Michigan, Ann Arbor, MI, USA. henke@umich.edu
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D002985:Clinical Protocols; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D007866:Leg / Q000098:blood supply*; D019990:Perioperative Care; D016491:Peripheral Vascular Diseases / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D014654:Vascular Patency; D014656:Vascular Surgical Procedures / Q000379:methods; D014665:Vasodilator Agents / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000925:Anticoagulants; D000959:Antihypertensive Agents; D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents